NDA Group today announced the appointment of Andrew Monaghan, PhD as General Manager for NDA’s UK affiliate based in London. Andrew brings over 35 years’ of experience in the drug development industry to the well-established UK team of close to 50 consultants and support staff.
Under Andrew’s leadership, drug developing companies from all over the world can expect a continuation of the many years of high-quality development consulting that the NDA Group has made a reputation for.
“I’m delighted to welcome Andrew on-board to join our highly skilled UK team,” commented Johan Strömquist CEO of NDA Group. “Andrew brings a wealth of experience to us and our clients and under his leadership we will continue to expand our impressive capabilities in the UK.”
As the new UK General Manager, Andrew will be responsible for developing, managing and driving the UK NDA team and business. Through his background Andrew has extensive experience of the challenges and opportunities in the biopharma industry.
“I am excited to join the NDA team and supporting NDA’s mission to help get the best medicines to patients with minimal delay” said Andrew. “I look forward to using my experience and knowledge to continue to build upon the fantastic work already done in the UK and supporting the growth of our global services.”
“From Andrew clients can expect not only great technical knowledge, but also a deep understanding of how drug development organisations work and operate” continues Johan Strömquist. “The demands on pharma and biotech companies are continually increasing and to navigate these waters requires the type of experience that he brings to the table”.
Prior to joining NDA Andrew worked at Worldwide Clinical trials as Global Head of Pharmacovigilance. He was responsible for all aspects of global Pharmacovigilance, including the development and management of teams in both Europe and North America.
His previous pharmaceutical positions include: Head of Pharmacovigilance at Chiltern. Andrew was at Roche/Genentech for 14 years, where he started as EU Head of Regulatory Affairs and Global Head of Medical Writing, before taking on the role of Global Head of Clinical Management and then the Global Head of Drug Safety Operations. He worked for Pfizer Central Research for 14 years, while in the UK he was responsible for the clinical development of a NCE and produced the clinical documents for the NDA/MAA, he then moved to the DRA group in the USA to manage its successful passage through FDA. Andrew has been involved the implementation of new technologies, enhancing business processes, and also improving organisational effectiveness.
NDA media contact: email@example.com
NDA is an independent consulting group with offices in Stockholm, London, Zürich, Munich, Princeton, Boston and San Francisco. Its mission is to ensure that good medicines reach patients without unnecessary delay. It accomplishes this by providing the pharmaceutical industry with a comprehensive range of professional drug development services focusing on regulatory affairs, health technology assessment, pharmacovigilance and quality assurance. NDA’s team of more than 150 full time professionals is comprised of more than 25% ex-regulators from major EU Agencies, and a specialist Advisory Board consisting of Europe’s leading regulatory and HTA experts. The NDA Advisory Board provides scientific advice to pharmaceutical companies supporting them in gaining fast and constructive assessment of applications from regulatory agencies and HTA bodies. www.ndareg.com